• 1. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 2. Excitonic and vibrational coherence in artificial photosynthetic systems studied by negative-time ultrafast laser spectroscopy
  Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Professional Introduction to Compound with CAS No. 1420804-01-8 and Product Name: 2-Azaspiro[4.5]decan-8-ylmethanamine

The compound with the CAS number 1420804-01-8 and the product name 2-Azaspiro[4.5]decan-8-ylmethanamine represents a significant advancement in the field of pharmaceutical chemistry. This spirocyclic amine derivative has garnered considerable attention due to its unique structural features and potential biological activities. The spirocyclic framework, characterized by a nitrogen-containing heterocycle linked to a decane backbone, introduces a high degree of molecular rigidity and conformational stability, which are critical factors in drug design. Such structural motifs have been increasingly explored in recent years for their ability to modulate enzyme activity and interact with biological targets in a highly specific manner.

In the context of modern drug discovery, the significance of 2-Azaspiro[4.5]decan-8-ylmethanamine lies in its potential applications as a lead compound or intermediate in the synthesis of novel therapeutic agents. The presence of the azaspiro structure suggests that this compound may exhibit properties such as enhanced binding affinity, reduced metabolic clearance, and improved pharmacokinetic profiles. These attributes are particularly valuable in the development of drugs targeting complex diseases such as cancer, neurodegenerative disorders, and inflammatory conditions.

Recent research has highlighted the importance of spirocyclic compounds in medicinal chemistry. For instance, studies have demonstrated that spirocyclic azines can serve as effective scaffolds for inhibiting various enzymes involved in disease pathways. The nitrogen atom in the azaspiro ring system can act as a hydrogen bond acceptor or participate in π-stacking interactions, which are crucial for optimizing binding interactions with biological targets. The flexibility provided by the methanamine side chain further allows for fine-tuning of the compound's pharmacophoric features, enabling precise modulation of biological activity.

The synthesis of 2-Azaspiro[4.5]decan-8-ylmethanamine involves sophisticated organic transformations that highlight the ingenuity of synthetic chemists in constructing complex molecular architectures. Key steps typically include ring-closing metathesis or cycloaddition reactions to form the spirocyclic core, followed by functional group modifications to introduce the desired substituents. Advances in catalytic methods have greatly facilitated the preparation of such compounds, making them more accessible for further investigation.

Biological evaluation of 2-Azaspiro[4.5]decan-8-ylmethanamine has revealed promising preliminary results. In vitro assays have shown that this compound exhibits inhibitory activity against certain enzymes relevant to cancer progression, such as kinases and proteases. Additionally, its interaction with cellular receptors has been studied to assess potential therapeutic effects on neurological disorders. The compound's ability to cross cell membranes and reach intracellular targets makes it an attractive candidate for further development.

The pharmacokinetic properties of 2-Azaspiro[4.5]decan-8-ylmethanamine are also of great interest. Studies using computational modeling have predicted favorable absorption, distribution, metabolism, and excretion (ADME) profiles, suggesting that it may exhibit good bioavailability and reduced toxicity. These predictions are supported by experimental data obtained from preclinical studies, which indicate that the compound is well-tolerated at relevant doses.

Future research directions for 2-Azaspiro[4.5]decan-8-ylmethanamine include structural optimization to enhance its potency and selectivity. By modifying substituents on the spirocyclic core or introducing additional functional groups, researchers aim to develop derivatives with improved pharmacological properties. Additionally, exploring new synthetic routes could reduce production costs and improve scalability, making this compound more viable for industrial applications.

The broader significance of 2-Azaspiro[4.5]decan-8-ylmethanamine lies in its contribution to the evolving landscape of drug discovery tools. As pharmaceutical companies continue to seek innovative molecular architectures for therapeutic agents, compounds like this one provide valuable starting points for developing next-generation drugs. The unique combination of structural rigidity and functional diversity offered by spirocyclic amines makes them particularly promising candidates for addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)